EAMA
FATE icon

EFG Asset Management (Americas)’s Fate Therapeutics FATE Stock Holding History

EFG Asset Management (Americas)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,804
Closed -$1.89M – 131
2022
Q1 		$1.89M Buy
48,804
+2,244
+5% +$86.9K 0.35% 70
2021
Q4 		$2.72M Buy
46,560
+7,291
+19% +$413K 0.46% 66
2021
Q3 		$2.33M Buy
39,269
+466
+1% +$36.6K 0.41% 71
2021
Q2 		$3.37M Buy
38,803
+4,540
+13% +$366K 0.63% 58
2021
Q1 		$2.83M Buy
+34,263
New +$3.28M 0.58% 64

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EFG Asset Management (Americas)'s FATE Position: Q2 2022 in Review

EFG Asset Management (Americas) sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 48,804 shares — an estimated $1.89M sold.

EFG Asset Management (Americas) first reported a position in FATE in Q1 2021 and held it in 5 quarters. The position peaked at $3.37M in Q2 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • EFG Asset Management (Americas) reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • EFG Asset Management (Americas) sold 48,804 Fate Therapeutics shares in Q2 2022, an estimated $1.89M.
  • EFG Asset Management (Americas) first reported a position in Fate Therapeutics in Q1 2021 and held it in 5 quarters.
  • EFG Asset Management (Americas)'s Fate Therapeutics position peaked at $3.37M in Q2 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on EFG Asset Management (Americas)'s 13F filing for Q2 2022, filed 13 Jul 2022.